Overview of methods for overcoming hindrance to drug delivery to tumors, with special attention to tumor interstitial fluid

Frontiers in Oncology

Volumn 5, Issue JUL, 2015, Pages

  Baronzio, Gianfranco ^a   Parmar, Gurdev ^b   Baronzio, Miriam ^a  

^a Medical Center Kines Oncology Section   (Italy)

^b Integrated Health Clinic   (Canada)

Author keywords

Adjuvant; Chemotherapy; Drug delivery systems; Tumor interstitial fluid; Tumor interstitial fluid pressure; Vascular normalization

Indexed keywords

ANGIOPOIETIN; BEVACIZUMAB; HYDRALAZINE; NOTCH4 RECEPTOR; NUTRACEUTICAL; PLATELET DERIVED GROWTH FACTOR; VASCULOTROPIN;

ANGIOGENESIS; BLOOD VESSEL PERMEABILITY; CANCER RADIOTHERAPY; CANCER THERAPY; CELL DENSITY; DRUG DELIVERY SYSTEM; EXTRACELLULAR MATRIX; HUMAN; HYPERTHERMIA; HYPOXIA; INTERSTITIAL FLUID; LASER DOPPLER FLOWMETRY; LYMPHANGIOGENESIS; NONHUMAN; PHOTODYNAMIC THERAPY; PROTEIN EXPRESSION; PROTEOMICS; REVIEW; TISSUE PRESSURE; TUMOR MICROENVIRONMENT; TUMOR VASCULARIZATION; ULTRASOUND THERAPY; UPREGULATION;

EID: 84940106291     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2015.00165     Document Type: Review

References (212)

1. Morgan G, Ward R, Barton M. The contribution of cytotoxic chemotherapy to 5-year survival in adult malignancies. Clin Oncol (R Coll Radiol) (2004) 16(8):549-60. doi: 10.1016/j.clon.2004.06.007.
2. Jain RK, Wei J, Gullino PM. Pharmacokinetics of methotrexate in solid tumors. J Pharmacokinet Biopharm (1979) 7(2):181-94. doi:10.1007/BF01059737.
3. Gullino PM, Clark SH, Grantham FH. The interstitial fluid of solid tumors. Cancer Res (1964) 24:780-94.
4. Grantham FH, Hill DM, Gullino PM. Primary mammary tumors connected to the host by a single artery and vein. J Natl Cancer Inst (1973) 50(5):1381-3.
5. Duyverman AM, Kohno M, Roberge S, Fukumura D, Duda DG, Jain RK. An isolated tumor perfusion model in mice. Nat Protoc (2012) 7(4):749-55. doi:10.1038/nprot.2012.030.
6. Tozer GM, Shaffi KM, Prise VE, Cunningham VJ. Characterisation of tumour blood flow using a 'tissue-isolated' preparation. Br J Cancer (1994) 70(6):1040-6. doi:10.1038/bjc.1994.445.
7. Jain RK. Barriers to drug delivery in solid tumors. Sci Am (1994) 271(1):58-65. doi:10.1038/scientificamerican0794-58.
8. Jain RK. Delivery of molecular and cellular medicine to solid tumors. Adv Drug Deliv Rev (2012) 64(Suppl):353-65. doi:10.1016/j.addr.2012.09.011.
9. Dellian M, Witwer BP, Salehi HA, Yuan F, Jain RK. Quantitation and physiological characterization of angiogenic vessels in mice: effect of basic fibroblast growth factor, vascular endothelial growth factor/vascular permeability factor, and host microenvironment. Am J Pathol (1996) 149(1):59-71.
10. Dellian M, Helmlinger G, Yuan F, Jain RK. Fluorescence ratio imaging of interstitial pH in solid tumours: effect of glucose on spatial and temporal gradients. Br J Cancer (1996) 74(8):1206-15. doi:10.1038/bjc.1996.518.
11. Jain RK. Transport of molecules in the tumor interstitium: a review. Cancer Res (1987) 47(12):3039-51.
12. Monsky WL. Circumventing anatomic and physiologic barriers to the intratumoral delivery of therapeutics. Anat Physiol (2012) 2:2-4. doi:10.4172/2161-0940.1000e114.
13. Sriraman SK, Aryasomayajula B, Torchilin VP. Barriers to drug delivery in solid tumors. Tissue Barriers (2014) 2:e29528. doi:10.4161/tisb.29528.
14. Narang AS, Varia S. Role of tumor vascular architecture in drug delivery. Adv Drug Deliv Rev (2011) 63(8):640-58. doi:10.1016/j.addr.2011.04.002.
15. Vaupel P, Mayer A. Hypoxia in tumors: pathogenesis-related classification, characterization of hypoxia subtypes, and associated biological and clinicalimplications. Adv Exp Med Biol (2014) 812:19-24. doi:10.1007/978-1-4939-0620-8_3.
16. Ramakrishnan S, Anand V, Roy S. Vascular endothelial growth factor signaling in hypoxia and inflammation. J Neuroimmune Pharmacol (2014) 9(2):142-60. doi:10.1007/s11481-014-9531-7.
17. Hirota K, Semenza GL. Regulation of angiogenesis by hypoxia-inducible factor 1. Crit Rev Oncol Hematol (2006) 59(1):15-26. doi:10.1016/j.critrevonc.2005.12.003.
18. Tie J, Desai J. Antiangiogenic therapies targeting the vascular endothelia growth factor signaling system. Crit Rev Oncog (2012) 17(1):51-67. doi:10.1615/CritRevOncog.v17.i1.50.
19. Shibuya M. Vascular endothelial growth factor and its receptor system: physiological functions in angiogenesis and pathological roles in various diseases. J Biochem (2013) 153(1):13-9. doi:10.1093/jb/mvs136.
20. Claesson-Welsh L, Welsh M. VEGFA and tumour angiogenesis. J Intern Med (2013) 273(2):114-27. doi:10.1111/joim.12019.
21. Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol (2005) 23(5):1011-27. doi:10.1200/JCO.2005.06.081.
22. Battegay EJ, Rupp J, Iruela-Arispe L, Sage EH, Pech M. PDGF-BB modulates endothelial proliferation and angiogenesis in vitro via PDGF beta-receptors. J Cell Biol (1994) 125(4):917-28. doi:10.1083/jcb.125.4.917.
23. Johnson KE, Wilgus TA. Vascular endothelial growth factor and angiogenesis in the regulation of cutaneous wound repair. Adv Wound Care (New Rochelle) (2014) 3(10):647-61. doi:10.1089/wound.2013.0517.
24. Chung AS, Ferrara N. Developmental and pathological angiogenesis. Annu Rev Cell Dev Biol (2011) 27:563-84. doi:10.1146/annurev-cellbio-092910-154002.
25. Riabov V, Gudima A, Wang N, Mickley A, Orekhov A, Kzhyshkowska J. Role of tumor associated macrophages in tumor angiogenesis and lymphangiogenesis. Front Physiol (2014) 5:75. doi:10.3389/fphys.2014.00075.
26. Furuya M, Yonemitsu Y, Aoki IIII. Angiogenesis: complexity of tumor vasculature and microenvironment. Curr Pharm Des (2009) 15(16):1854-67. doi:10.2174/138161209788453275.
27. Munn LL. Aberrant vascular architecture in tumors and its importance in drug-based therapies. Drug Discov Today (2003) 8(9):396-403. doi:10.1016/S1359-6446(03)02686-2.
28. Nagaraja S, Wallqvist A, Reifman J, Mitrophanov AY. Computational approach to characterize causative factors and molecular indicators of chronic wound inflammation. J Immunol (2014) 192(4):1824-34. doi:10.4049/jimmunol.1302481.
29. Konerding MA, Fait E, Gaumann A. 3D microvascular architecture of pre-cancerous lesions and invasive carcinomas of the colon. Br J Cancer (2001) 84(10):1354-62. doi:10.1054/bjoc.2001.1809.
30. Ackermann M, Konerding MA. Vascular casting for the study of vascular morphogenesis. Methods Mol Biol (2015) 1214:49-66. doi:10.1007/978-1-4939-1462-3_5.
31. Azzi S, Gavard J. [Blood vessels in cancer: can't stop whispering]. Med Sci (Paris) (2014) 30(4):408-14. doi:10.1051/medsci/20143004015.
32. Nagy JA, Dvorak AM, Dvorak HF. Vascular hyperpermeability, angiogenesis, and stroma generation. Cold Spring Harb Perspect Med (2012) 2(2):a006544. doi:10.1101/cshperspect.a006544.
33. Roberts WG, Palade GE. Increased microvascular permeability and endothelial fenestration induced by vascular endothelial growth factor. J Cell Sci (1995) 108(Pt 6):2369-79.
34. Weis SM, Cheresh DA. Pathophysiological consequences of VEGF-induced vascular permeability. Nature (2005) 437(7058):497-504. doi:10.1038/nature03987.
35. Bates DO. Vascular endothelial growth factors and vascular permeability. Cardiovasc Res (2010) 87(2):262-71. doi:10.1093/cvr/cvq105.
36. Padera TP, Kadambi A, di Tomaso E, Carreira CM, Brown EB, Boucher Y, et al. Lymphatic metastasis in the absence of functional intratumor lymphatics. Science (2002) 296(5574):1883-6. doi:10.1126/science.1071420.
37. Jain RK, Fenton BT. Intratumoral lymphatic vessels: a case of mistaken identity or malfunction? J Natl Cancer Inst (2002) 94(6):417-21. doi:10.1093/jnci/94.6.417.
38. Wiig H, Swartz MA. Interstitial fluid and lymph formation and transport: physiological regulation and roles in inflammation and cancer. Physiol Rev (2012) 92(3):1005-60. doi:10.1152/physrev.00037.2011.
39. Wagner M, Wiig H. Tumor interstitial fluid formation, characterization, and clinical implications. Front Oncol (2015) 5:115. doi:10.3389/fonc.2015.00115.
40. Angelo LS, Kurzrock R. Vascular endothelial growth factor and its relationship to inflammatory mediators. Clin Cancer Res (2007) 13(10):2825-30. doi:10.1158/1078-0432.CCR-06-2416.
41. Landskron G, De la Fuente M, Thuwajit P, Thuwajit C, Hermoso MA. Chronic inflammation and cytokines in the tumor microenvironment. J Immunol Res (2014) 2014:149185. doi:10.1155/2014/149185.
42. Ono M. Molecular links between tumor angiogenesis and inflammation: inflammatory stimuli of macrophages and cancer cells as targets for therapeutic strategy. Cancer Sci (2008) 99(8):1501-6. doi:10.1111/j.1349-7006.2008.00853.x.
43. Gullino PM, Grantham FH, Smith SH. The interstitial water space of tumors. Cancer Res (1965) 25:727-31.
44. Gullino PM. The internal milieu of tumors. Prog Exp Tumor Res (1966) 8:1-25. doi:10.1159/000386002.
45. Gullino PM. Extracellular compartments of solid tumors. In: Becker FF, editor. Cancer a Comprehensive Treatise. New York, NY: Plenum Press (1975). p. 327-54.
46. Levick JR, Michel CC. Microvascular fluid exchange and the revised Starling principle. Cardiovasc Res (2010) 87(2):198-210. doi:10.1093/cvr/cvq062.
47. Baronzio G, Schwartz L, Kiselevsky M, Guais A, Sanders E, Milanesi G, et al. Tumor interstitial fluid as modulator of cancer inflammation,thrombosis, immunity and angiogenesis. Anticancer Res (2012) 32(2):405-14.
48. Aukland K, Reed RK. Interstitial-lymphatic mechanisms in the control of extracellular fluid volume. Physiol Rev (1993) 73(1):1-78.
49. Jain RK. Delivery of molecular and cellular medicine to solid tumors. J Control Release (1998) 53(1-3):49-67. doi:10.1016/S0168-3659(97)00237-X.
50. Jain RK. Determinants of tumor blood flow: a review. Cancer Res (1988) 48(10):2641-58.
51. Sylven B, Bois I. Protein content and enzymatic assays of interstitial fluid from some normal tissues and transplanted mouse tumors. Cancer Res (1960) 20:831-6.
52. Gullino PM, Grantham FH, Clark SH. The collagen content of transplanted tumors. Cancer Res (1962) 22:1031-7.
53. Gromov P, Gromova I, Olsen CJ, Timmermans-Wielenga V, Talman ML, Serizawa RR, et al. Tumor interstitial fluid-a treasure trove of cancer biomarkers. Biochim Biophys Acta (2013) 1834(11):2259-70. doi:10.1016/j.bbapap.2013.01.013.
54. Haslene-Hox H, Tenstad O, Wiig H. Interstitial fluid-a reflection of the tumor cell microenvironment and secretome. Biochim Biophys Acta (2013) 1834(11):2336-46. doi:10.1016/j.bbapap.2013.01.028.
55. Guyton AC. Pressure-volume relationships in the interstitial spaces. Invest Ophthalmol (1965) 4(6):1075-84.
56. Guyton AC, Granger HJ, Taylor AE. Interstitial fluid pressure. Physiol Rev (1971) 51(3):527-63.
57. Ariffin AB, Forde PF, Jahangeer S, Soden DM, Hinchion J. Releasing pressure in tumors: what do we know so far and where do we go from here? A review. Cancer Res (2014) 74(10):2655-62. doi:10.1158/0008-5472.CAN-13-3696.
58. Stapleton S, Milosevic MF. Pressure gradients in solid tumors. In: Bae YH, Mrsny RJ, Park K, editors. Cancer Target Drug Delivery. Springer (2013). p. 241-72.
59. Young JS, Lumsden CE, Stalker AL. The significance of the tissue pressure of normal testicular and of neoplastic (Brown-Pearce carcinoma) tissue in the rabbit. J Pathol Bacteriol (1950) 62(3):313-33. doi:10.1002/path.1700620303.
60. Jain RK. Physiological resistance to the treatment of solid tumors. In: Teicher BA, editor. Drug Resistance in Oncology. Marcel Dekker (1993). p. 87-105.
61. Lunt SJ, Fyles A, Hill RP, Milosevic M. Interstitial fluid pressure in tumors:therapeutic barrier and biomarker of angiogenesis. Future Oncol (2008) 4(6):793-802. doi:10.2217/14796694.4.6.793.
62. Milosevic M, Fyles A, Hedley D, Hill R. The human tumor microenvironment:invasive (needle) measurement of oxygen and interstitial fluid pressure. Semin Radiat Oncol (2004) 14(3):249-58. doi:10.1016/j.semradonc.2004.04.006.
63. Jain RK, Chauhan VP, Duda DG. Vascular and interstitial biology of tumors. Abeloff Clinical Oncology Textbook (2014). p. 108-26.
64. Butler TP, Grantham FH, Gullino PM. Bulk transfer of fluid in the interstitial compartment of mammary tumors. Cancer Res (1975) 35(11 Pt 1):3084-8.
65. Munson JM, Shieh AC. Interstitial fluid flow in cancer: implications for disease progression and treatment. Cancer Manag Res (2014) 6:317-28. doi:10.2147/CMAR.S65444.
66. Hompland T, Ellingsen C, Øvrebø KM, Rofstad EK. Interstitial fluid pressure and associated lymph node metastasis revealed in tumors by dynamic contrast-enhanced MRI. Cancer Res (2012) 72(19):4899-908. doi:10.1158/0008-5472.CAN-12-0903.
67. Chary SR, Jain RK. Direct measurement of interstitial convection and diffusion of albumin in normal and neoplastic tissues by fluorescence photobleaching. Proc Natl Acad Sci U S A (1989) 86(14):5385-9. doi:10.1073/pnas.86.14.5385.
68. Pathak AP, Artemov D, Ward BD, Jackson DG, Neeman M, Bhujwalla ZM. Characterizing extravascular fluid transport of macromolecules in the tumor interstitium by magnetic resonance imaging. Cancer Res (2005) 65(4):1425-32. doi:10.1158/0008-5472.CAN-04-3682.
69. Yao W, Shen Z, Ding G. Simulation of interstitial fluid flow in ligaments: comparison among Stokes, Brinkman and Darcy models. Int J Biol Sci (2013) 9(10):1050-6. doi:10.7150/ijbs.7242.
70. Rofstad EK, Galappathi K, Mathiesen BS. Tumor interstitial fluid pressure-a link between tumor hypoxia, microvascular density, and lymph node metastasis. Neoplasia (2014) 16(7):586-94. doi:10.1016/j.neo.2014.07.003.
71. Swartz MA. Immunomodulatory roles of lymphatic vessels in cancer progression. Cancer Immunol Res (2014) 2(8):701-7. doi:10.1158/2326-6066.CIR-14-0115.
72. Rutkowski JM, Swartz MA. A driving force for change: interstitial flow as a morphoregulator. Trends Cell Biol (2007) 17(1):44-50. doi:10.1016/j.tcb.2006.11.007.
73. Ng CP, Hinz B, Swartz MA. Interstitial fluid flow induces myofibroblast differentiation and collagen alignment in vitro. J Cell Sci (2005) 118(Pt20):4731-9. doi:10.1242/jcs.02605.
74. Shields JD, Fleury ME, Yong C, Tomei AA, Randolph GJ, Swartz MA. Autologous chemotaxis as a mechanism of tumor cell homing to lymphatics via interstitial flow and autocrine CCR7 signaling. Cancer Cell (2007) 11(6):526-38. doi:10.1016/j.ccr.2007.04.020.
75. Multhoff G, Vaupel P. Radiation-induced changes in microcirculation and interstitial fluid pressure affecting the delivery of macromolecules and nanotherapeutics to tumors. Front Oncol (2012) 2:165. doi:10.3389/fonc.2012.00165.
76. Yuan F. Transvascular drug delivery in solid tumors. Semin Radiat Oncol (1998) 8(3):164-75. doi:10.1016/S1053-4296(98)80042-8.
77. Sarin H. Physiologic upper limits of pore size of different blood capillary types and another perspective on the dual pore theory of microvascular permeability. J Angiogenes Res (2010) 2:14. doi:10.1186/2040-2384-2-14.
78. Monsky WL, Fukumura D, Gohongi T, Ancukiewcz M, Weich HA, Torchilin VP, et al. Augmentation of transvascular transport of macromolecules and nanoparticles in tumors using vascular endothelial growth factor. Cancer Res (1999) 59(16):4129-35.
79. Pusenjak J, Miklavcic D. Interstitial fluid pressue as an obstacle in treatment of solid tumors. Radiol Oncol (1997) 31:291-7.
80. Swabb EA, Wei J, Gullino PM. Diffusion and convection in normal and neoplastic tissues. Cancer Res (1974) 34(10):2814-22.
81. Netti P, Jain RK. Interstitial transport in solid tumours. Cancer Modelling and Simulation. Chapman&Hall/CRC press (2003). p. 51-74.
82. Welter M, Rieger H. Interstitial fluid flow and drug delivery in vascularized tumors: a computational model. PLoS One (2013) 8(8):e70395. doi:10.1371/journal.pone.0070395.
83. Soltani M, Chen P. Numerical modeling of fluid flow in solid tumors. PLoS One (2011) 6(6):e20344. doi:10.1371/journal.pone.0020344.
84. Soltani M, Chen P. Numerical modeling of interstitial fluid flow coupled with blood flow through a remodeled solid tumor microvascular network. PLoS One (2013) 8(6):e67025. doi:10.1371/journal.pone.0067025.
85. Stapleton S, Milosevic M, Allen C, Zheng J, Dunne M, Yeung I, et al. A mathematical model of the enhanced permeability and retention effect for liposome transport in solid tumors. PLoS One (2013) 8(12):e81157. doi:10.1371/journal.pone.0081157.
86. Wiig H, Reed RK, Aukland K. Measurement of interstitial fluid pressure: comparison of methods. Ann Biomed Eng (1986) 14(2):139-51. doi:10.1007/BF02584264.
87. Wiig H. Evaluation of methodologies for measurement of interstitial fluid pressure (Pi): physiological implications of recent Pi data. Crit Rev Biomed Eng (1990) 18(1):27-54.
88. Hargens AR, Cologne JB, Menninger FJ, Hogan JS, Tucker BJ, Peters RM. Normal transcapillary pressures in human skeletal muscle and subcutaneous tissues. Microvasc Res (1981) 22(2):177-89. doi:10.1016/0026-2862(81)90087-X.
89. Scholander PF, Hargens AR, Miller SL. Negative pressure in the interstitial fluid of animals. Fluid tensions are spectacular in plants; in animals they are elusively small, but just as vital. Science (1968) 161(3839):321-8. doi:10.1126/science.161.3839.321.
90. Fadnes HO, Reed RK, Aukland K. Interstitial fluid pressure in rats measured with a modified wick technique. Microvasc Res (1977) 14(1):27-36. doi:10.1016/0026-2862(77)90138-8.
91. Wiederhielm CA, Weston BV. Microvascular, lymphatic, and tissue pressures in the unanesthetized mammal. Am J Physiol (1973) 225(4):992-6.
92. Wiig H, Reed RK, Aukland K. Micropuncture measurement of interstitial fluid pressure in rat subcutis and skeletal muscle: comparison to wick-in-needle technique. Microvasc Res (1981) 21(3):308-19. doi:10.1016/0026-2862(81)90014-5.
93. Wiig H. Comparison of methods for measurement of interstitial fluid pressure in cat skin/subcutis and muscle. Am J Physiol (1985) 249(5 Pt 2):H929-44.
94. Tatsuo T, Toshiyo T, Oberg P. Pressure measurement. Biomedical Transducers and Instruments. CRC press (1997). p. 13-70.
95. Curti BD, Urba WJ, Alvord WG, Janik JE, Smith JW II, Madara K, et al. Interstitial pressure of subcutaneous nodules in melanoma and lymphoma patients:changes during treatment. Cancer Res (1993) 53(10 Suppl):2204-7.
96. Lyng H, Tufto I, Skretting A, Rofstad EK. Proton relaxation times and interstitial fluid pressure in human melanoma xenografts. Br J Cancer (1997) 75(2):180-3. doi:10.1038/bjc.1997.30.
97. Hassid Y, Furman-Haran E, Margalit R, Eilam R, Degani H. Noninvasive magnetic resonance imaging of transport and interstitial fluid pressure in ectopic human lung tumors. Cancer Res (2006) 66(8):4159-66. doi:10.1158/0008-5472.CAN-05-3289.
98. Hassid Y, Eyal E, Margalit R, Furman-Haran E, Degani H. Non-invasive imaging of barriers to drug delivery in tumors. Microvasc Res (2008) 76(2):94-103. doi:10.1016/j.mvr.2008.06.002.
99. Gade TP, Buchanan IM, Motley MW, Mazaheri Y, Spees WM, Koutcher JA. Imaging intratumoral convection: pressure-dependent enhancement in chemotherapeutic delivery to solid tumors. Clin Cancer Res (2009) 15(1):247-55. doi:10.1158/1078-0432.CCR-08-0611.
100. van der Veldt AA, Smit EF, Lammertsma AA. Positron emission tomography as a method for measuring drug delivery to tumors in vivo: the example of [(11)C]docetaxel. Front Oncol (2013) 3:208. doi:10.3389/fonc.2013.00208.
101. Heldin CH, Rubin K, Pietras K, Ostman A. High interstitial fluid pressure-an obstacle in cancer therapy. Nat Rev Cancer (2004) 4(10):806-13. doi:10.1038/nrc1456.
102. Jain RK. Physiological barriers to delivery of monoclonal antibodies and other macromolecules in tumors. Cancer Res (1990) 50(3 Suppl):814s-9s.
103. Christiansen J, Rajasekaran AK. Biological impediments to monoclonal antibody-based cancer immunotherapy. Mol Cancer Ther (2004) 3(11):1493-501.
104. Chauhan VP, Stylianopoulos T, Boucher Y, Jain RK. Delivery of molecular and nanoscale medicine to tumors: transport barriers and strategies. Annu Rev Chem Biomol Eng (2011) 2:281-98. doi:10.1146/annurev-chembioeng-061010-114300.
105. Campbell RB. Tumor physiology and delivery of nanopharmaceuticals. Anticancer Agents Med Chem (2006) 6(6):503-12. doi:10.2174/187152006778699077.
106. Jain M, Venkatraman G, Batra SK. Optimization of radioimmunotherapy of solid tumors: biological impediments and their modulation. Clin Cancer Res (2007) 13(5):1374-82. doi:10.1158/1078-0432.CCR-06-2436.
107. Stylianopoulos T, Martin JD, Snuderl M, Mpekris F, Jain SR, Jain RK. Coevolution of solid stress and interstitial fluid pressure in tumors during progression: implications for vascular collapse. Cancer Res (2013) 73(13):3833-41. doi:10.1158/0008-5472.
108. Salnikov AV, Iversen VV, Koisti M, Sundberg C, Johansson L, Stuhr LB, et al. Lowering of tumor interstitial fluid pressure specifically augments efficacy of chemotherapy. FASEB J (2003) 17(12):1756-8.
109. Leunig M, Goetz AE, Gamarra F, Zetterer G, Messmer K, Jain RK. Photodynamic therapy-induced alterations in interstitial fluid pressure, volume and water content of an amelanotic melanoma in the hamster. Br J Cancer (1994) 69(1):101-3. doi:10.1038/bjc.1994.15.
110. Chauhan VP, Martin JD, Liu H, Lacorre DA, Jain SR, Kozin SV, et al. Angiotensin inhibition enhances drug delivery and potentiates chemotherapy by decompressing tumour blood vessels. Nat Commun (2013) 4:2516. doi:10.1038/ncomms3516.
111. Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science (2005) 307(5706):58-62. doi:10.1126/science.1104819.
112. Chauhan VP, Stylianopoulos T, Martin JD, Popovic Z, Chen O, Kamoun WS, et al. Normalization of tumour blood vessels improves the delivery of nanomedicines in a size-dependent manner. Nat Nanotechnol (2012) 7(6):383-8. doi:10.1038/nnano.2012.45.
113. Huang Y, Stylianopoulos T, Duda DG, Fukumura D, Jain RK. Benefits of vascular normalization are dose and time dependent-letter. Cancer Res (2013) 73(23):7144-6. doi:10.1158/0008-5472.
114. Arjaans M, Oude Munnink TH, Oosting SF, Terwisscha van Scheltinga AG, Gietema JA, Garbacik ET, et al. Bevacizumab-induced normalization of blood vessels in tumors hampers antibody uptake. Cancer Res (2013) 73(11):3347-55. doi:10.1158/0008-5472.CAN-12-3518.
115. Huang Y, Goel S, Duda DG, Fukumura D, Jain RK. Vascular normalization as an emerging strategy to enhance cancer immunotherapy. Cancer Res (2013) 73(10):2943-8. doi:10.1158/0008-5472.CAN-12-4354.
116. Balamurugan K. HIF-1 at the crossroads of hypoxia, inflammation, and cancer. Int J Cancer (2015). doi:10.1002/ijc.29519.
117. Shrimali RK, Yu Z, Theoret MR, Chinnasamy D, Restifo NP, Rosenberg SA. Antiangiogenic agents can increase lymphocyte infiltration into tumor and enhance the effectiveness of adoptive immunotherapy of cancer. Cancer Res (2010) 70(15):6171-80. doi:10.1158/0008-5472.CAN-10-0153.
118. Heist RS, Duda DG, Sahani DV, Ancukiewicz M, Fidias P, Sequist LV, et al. Improved tumor vascularization after anti-VEGF therapy with carboplatin and nab-paclitaxel associates with survival in lung cancer. Proc Natl Acad Sci U S A (2015) 112(5):1547-52. doi:10.1073/pnas.1424024112.
119. Gaya AM, Rustin GJ. Vascular disrupting agents: a new class of drug in cancer therapy. Clin Oncol (R Coll Radiol) (2005) 17(4):277-90. doi:10.1016/j.clon.2004.11.011.
120. Skliarenko JV, Lunt SJ, Gordon ML, Vitkin A, Milosevic M, Hill RP. Effects of the vascular disrupting agent ZD6126 on interstitial fluid pressure and cell survival in tumors. Cancer Res (2006) 66(4):2074-80. doi:10.1158/0008-5472.CAN-05-2046.
121. Ley CD, Horsman MR, Kristjansen PE. Early effects of combretastatin-A4 disodium phosphate on tumor perfusion and interstitial fluid pressure. Neoplasia (2007) 9(2):108-12.
122. Zlotecki RA, Baxter LT, Boucher Y, Jain RK. Pharmacologic modification of tumor blood flow and interstitial fluid pressure in a human tumor xenograft:network analysis and mechanistic interpretation. Microvasc Res (1995) 50(3):429-43. doi:10.1006/mvre.1995.1069.
123. Vaupel P. Oxygenation of solid tumors. In: Teicher BA, editor. Drug Resistance in Oncology. New York, NY: Marcel Dekker Inc (1993). p. 53-85.
124. Podobnik B, Sersa G, Miklavcic D. Effect of hydralazine on interstitial fluid pressure in experimental tumours and in normal tissue. In Vivo (2001) 15(5):417-24.
125. Jarm T, Podobnik B, Sersa G, Miklavcic D. Effect of hydralazine on blood flow, oxygenation, and interstitial fluid pressure in subcutaneous tumors. Adv Exp Med Biol (2003) 10:25-9. doi:10.1007/978-1-4615-0205-0_5.
126. Brønstad A, Berg A, Reed RK. Effects of the taxanes paclitaxel and docetaxel on edema formation and interstitial fluid pressure. Am J Physiol Heart Circ Physiol (2004) 287(2):H963-8. doi:10.1152/ajpheart.01052.2003.
127. Griffon-Etienne G, Boucher Y, Brekken C, Suit HD, Jain RK. Taxane-induced apoptosis decompresses blood vessels and lowers interstitial fluid pressure in solid tumors: clinical implications. Cancer Res (1999) 59(15):3776-82.
128. Taghian AG, Abi-Raad R, Assaad SI, Casty A, Ancukiewicz M, Yeh E, et al. Paclitaxel decreases the interstitial fluid pressure and improves oxygenation in breast cancers in patients treated with neoadjuvant chemotherapy: clinical implications. J Clin Oncol (2005) 23(9):1951-61. doi:10.1200/JCO.2005.08.119.
129. Aapro MS, Alberts DS. High-dose dexamethasone for prevention of cis-platin-induced vomiting. Cancer Chemother Pharmacol (1981) 7(1):11-4. doi:10.1007/BF00258206.
130. Wang H, Li M, Rinehart JJ, Zhang R. Pretreatment with dexamethasone increases antitumor activity of carboplatin and gemcitabine in mice bearing human cancer xenografts: in vivo activity, pharmacokinetics, and clinical implications for cancer chemotherapy. Clin Cancer Res (2004) 10(5):1633-44. doi:10.1158/1078-0432.CCR-0829-3.
131. Kristjansen PE, Boucher Y, Jain RK. Dexamethasone reduces the interstitial fluid pressure in a human colon adenocarcinoma xenograft. Cancer Res (1993) 53(20):4764-6.
132. Hahn GM. Hyperthermia for the engineer: a short biological primer. IEEE Trans Biomed Eng (1984) 31(1):3-8. doi:10.1109/TBME.1984.325363.
133. Leunig M, Goetz AE, Dellian M, Zetterer G, Gamarra F, Jain RK, et al. Interstitial fluid pressure in solid tumors following hyperthermia: possible correlation with therapeutic response. Cancer Res (1992) 52(2):487-90.
134. Sen A, Capitano ML, Spernyak JA, Schueckler JT, Thomas S, Singh AK, et al. Mild elevation of body temperature reduces tumor interstitial fluid pressure and hypoxia and enhances efficacy of radiotherapy in murine tumor models. Cancer Res (2011) 71(11):3872-80. doi:10.1158/0008-5472.CAN-10-4482.
135. Rofstad EK, Gaustad JV, Brurberg KG, Mathiesen B, Galappathi K, Simonsen TG. Radiocurability is associated with interstitial fluid pressure in human tumor xenografts. Neoplasia (2009) 11(11):1243-51. doi:10.1593/neo.91152.
136. Znati CA, Rosenstein M, Boucher Y, Epperly MW, Bloomer WD, Jain RK. Effect of radiation on interstitial fluid pressure and oxygenation in a human tumorxenograft. Cancer Res (1996) 56(5):964-8.
137. Agostinis P, Berg K, Cengel KA, Foster TH, Girotti AW, Gollnick SO, et al. Photodynamic therapy of cancer: an update. CA Cancer J Clin (2011) 61(4):250-81. doi:10.3322/caac.20114.
138. Castano AP, Mroz P, Hamblin MR. Photodynamic therapy and anti-tumour immunity. Nat Rev Cancer (2006) 6(7):535-45. doi:10.1038/nrc1894.
139. Perentes JY, Wang Y, Wang X, Abdelnour E, Gonzalez M, Decosterd L, et al. Low-dose vascular photodynamic therapy decreases tumor interstitial fluid pressure, which promotes liposomal doxorubicin distribution in a murine sarcoma metastasis model. Transl Oncol (2014) 7(3):393-9. doi:10.1016/j.tranon.2014.04.010.
140. Zhou Y. Ultrasound-mediated drug/gene delivery in solid tumor treatment. J Healthc Eng (2013) 4(2):223-54. doi:10.1260/2040-2295.4.2.223.
141. Watson KD, Lai CY, Qin S, Kruse DE, Lin YC, Seo JW, et al. Ultrasound increases nanoparticle delivery by reducing intratumoral pressure and increasing transport in epithelial and epithelial-mesenchymal transition tumors. Cancer Res (2012) 72(6):1485-93. doi:10.1158/0008-5472.CAN-11-3232.
142. Nurwidya F, Takahashi F, Murakami A, Takahashi K. Epithelial mesenchymal transition in drug resistance and metastasis of lung cancer. Cancer Res Treat (2012) 44(3):151-6. doi:10.4143/crt.2012.44.3.151.
143. Kalluri R, Weinberg RA. The basics of epithelial-mesenchymal transition. J Clin Invest (2009) 119(6):1420-8. doi:10.1172/JCI39104.
144. Diop-Frimpong B, Chauhan VP, Krane S, Boucher Y, Jain RK. Losartan inhibits collagen I synthesis and improves the distribution and efficacy of nanotherapeutics in tumors. Proc Natl Acad Sci U S A (2011) 108(7):2909-14. doi:10.1073/pnas.1018892108.
145. Netti PA, Berk DA, Swartz MA, Grodzinsky AJ, Jain RK. Role of extracellular matrix assembly in interstitial transport in solid tumors. Cancer Res (2000) 60(9):2497-503.
146. Lu P, Weaver VM, Werb Z. The extracellular matrix: a dynamic niche in cancer progression. J Cell Biol (2012) 196(4):395-406. doi:10.1083/jcb.201102147.
147. Öhlund D, Elyada E, Tuveson D. Fibroblast heterogeneity in the cancer wound. J Exp Med (2014) 211(8):1503-23. doi:10.1084/jem.20140692.
148. Schaefer L, Iozzo RV. Biological functions of the small leucine-rich proteoglycans: from genetics to signal transduction. J Biol Chem (2008) 283(31):21305-9. doi:10.1074/jbc.R800020200.
149. Bonnans C, Chou J, Werb Z. Remodelling the extracellular matrix in development and disease. Nat Rev Mol Cell Biol (2014) 15(12):786-801. doi:10.1038/nrm3904.
150. Kim SH, Turnbull J, Guimond S. Extracellular matrix and cell signalling: the dynamic cooperation of integrin, proteoglycan and growth factor receptor. J Endocrinol (2011) 209(2):139-51. doi:10.1530/JOE-10-0377.
151. Eikenes L, Bruland ØS, Brekken C, Davies Cde L. Collagenase increases the transcapillary pressure gradient and improves the uptake and distribution of monoclonal antibodies in human osteosarcoma xenografts. Cancer Res (2004) 64(14):4768-73. doi:10.1158/0008-5472.CAN-03-1472.
152. Eikenes L, Tari M, Tufto I, Bruland OS, de Lange Davies C. Hyaluronidase induces a transcapillary pressure gradient and improves the distribution and uptake of liposomal doxorubicin (Caelyx) in human osteosarcoma xenografts. Br J Cancer (2005) 93(1):81-8. doi:10.1038/sj.bjc.6602626.
153. Papageorgis P, Stylianopoulos T. Role of TGFβ in regulation of the tumor microenvironment and drug delivery (review). Int J Oncol (2015) 46(3):933-43. doi:10.3892/ijo.2015.2816.
154. Pietras K, Rubin K, Sjöblom T, Buchdunger E, Sjöquist M, Heldin CH, et al. Inhibition of PDGF receptor signaling in tumor stroma enhances antitumor effect of chemotherapy. Cancer Res (2002) 62(19):5476-84.
155. Baranowska-Kortylewicz J, Abe M, Pietras K, Kortylewicz ZP, Kurizaki T, Nearman J, et al. Effect of platelet-derived growth factor receptor-beta inhibition with STI571 on radioimmunotherapy. Cancer Res (2005) 65(17):7824-31. doi:10.1158/0008-5472.CAN-04-3991.
156. Brekken C, Bruland ØS, de Lange Davies C. Interstitial fluid pressure in human osteosarcoma xenografts: significance of implantation site and the response to intratumoral injection of hyaluronidase. Anticancer Res (2000) 20(5B):3503-12.
157. Heuchel R, Berg A, Tallquist M, Ahlén K, Reed RK, Rubin K, et al. Platelet-derived growth factor beta receptor regulates interstitial fluid homeostasis through phosphatidylinositol-3' kinase signaling. Proc Natl Acad Sci U S A (1999) 96(20):11410-5. doi:10.1073/pnas.96.20.11410.
158. Egeblad M, Rasch MG, Weaver VM. Dynamic interplay between the collagen scaffold and tumor evolution. Curr Opin Cell Biol (2010) 22(5):697-706. doi:10.1016/j.ceb.2010.08.015.
159. Zhong Z, Carroll KD, Policarpio D, Osborn C, Gregory M, Bassi R, et al. Anti-transforming growth factor beta receptor II antibody has therapeutic efficacy against primary tumor growth and metastasis through multieffects on cancer, stroma, and immune cells. Clin Cancer Res (2010) 16(4):1191-205. doi:10.1158/1078-0432.CCR-09-1634.
160. Loeffler M, Krüger JA, Niethammer AG, Reisfeld RA. Targeting tumor-associated fibroblasts improves cancer chemotherapy by increasing intratumoral drug uptake. J Clin Invest (2006) 116(7):1955-62. doi:10.1172/JCI26532.
161. Bouzin C, Feron O. Targeting tumor stroma and exploiting mature tumor vasculature to improve anti-cancer drug delivery. Drug Resist Updat (2007) 10(3):109-20. doi:10.1016/j.drup.2007.03.001.
162. Deng PB, Hu CP, Xiong Z, Yang HP, Li YY. Treatment with EGCG in NSCLC leads to decreasing interstitial fluid pressure and hypoxia to improve chemotherapy efficacy through rebalance of Ang-1 and Ang-2. Chin J Nat Med (2013) 11(3):245-53. doi:10.1016/S1875-5364(13)60023-0.
163. Kornfeld S, Goupille C, Vibet S, Chevalier S, Pinet A, Lebeau J, et al. Reducing endothelial NOS activation and interstitial fluid pressure with n-3 PUFA offset tumor chemoresistance. Carcinogenesis (2012) 33(2):260-7. doi:10.1093/carcin/bgr274.
164. Shim WS, Ho IA, Wong PE. Angiopoietin: a TIE(d) balance in tumor angiogenesis. Mol Cancer Res (2007) 5(7):655-65. doi:10.1158/1541-7786.MCR-07-0072.
165. Merendino N, Costantini L, Manzi L, Molinari R, D'Eliseo D, Velotti F. Dietary ω-3 polyunsaturated fatty acid DHA: a potential adjuvant in the treatment of cancer. Biomed Res Int (2013) 2013:310186. doi:10.1155/2013/310186.
166. Au JL, Jang SH, Wientjes MG. Clinical aspects of drug delivery to tumors. J Control Release (2002) 78(1-3):81-95. doi:10.1016/S0168-3659(01)00488-6.
167. Au JL, Jang SH, Zheng J, Chen CT, Song S, Hu L, et al. Determinants of drug delivery and transport to solid tumors. J Control Release (2001) 74(1-3):31-46. doi:10.1016/S0168-3659(01)00308-X.
168. Trédan O, Galmarini CM, Patel K, Tannock IF. Drug resistance and the solid tumor microenvironment. J Natl Cancer Inst (2007) 99(19):1441-54. doi:10.1093/jnci/djm135.
169. Solyanik GI. Multifactorial nature of tumor drug resistance. Exp Oncol (2010) 32(3):181-5.
170. Saggar JK, Yu M, Tan Q, Tannock IF. The tumor microenvironment and strategies to improve drug distribution. Front Oncol (2013) 3:154. doi:10.3389/fonc.2013.00154.
171. Minchinton AI, Tannock IF. Drug penetration in solid tumours. Nat Rev Cancer (2006) 6(8):583-92. doi:10.1038/nrc1893.
172. Grantab RH, Tannock IF. Penetration of anticancer drugs through tumour tissue as a function of cellular packing density and interstitial fluid pressure and its modification by bortezomib. BMC Cancer (2012) 12:214. doi:10.1186/1471-2407-12-214.
173. Croix BS, Rak JW, Kapitain S, Sheehan C, Graham CH, Kerbel RS. Reversal by hyaluronidase of adhesion-dependent multicellular drug resistance in mammary carcinoma cells. J Natl Cancer Inst (1996) 88(18):1285-96. doi:10.1093/jnci/88.18.1285.
174. Mehta AI, Choi BD, Ajay D, Raghavan R, Brady M, Friedman AH, et al. Convection enhanced delivery of macromolecules for brain tumors. Curr Drug Discov Technol (2012) 9(4):305-10. doi:10.2174/157016312803305951.
175. Bobo RH, Laske DW, Akbasak A, Morrison PF, Dedrick RL, Oldfield EH. Convection-enhanced delivery of macromolecules in the brain. Proc Natl Acad Sci U S A (1994) 91(6):2076-80. doi:10.1073/pnas.91.6.2076.
176. Debinski W, Tatter SB. Convection-enhanced delivery for the treatment of brain tumors. Expert Rev Neurother (2009) 9(10):1519-27. doi:10.1586/ern.09.99.
177. Saito R, Bringas JR, McKnight TR, Wendland MF, Mamot C, Drummond DC, et al. Distribution of liposomes into brain and rat brain tumor models by convection-enhanced delivery monitored with magnetic resonance imaging. Cancer Res (2004) 64(7):2572-9. doi:10.1158/0008-5472.CAN-03-3631.
178. Vandergrift WA, Patel SJ, Nicholas JS, Varma AK. Convection-enhanced delivery of immunotoxins and radioisotopes for treatment of malignant gliomas. Neurosurg Focus (2006) 20(4):E13. doi:10.3171/foc.2006.20.4.8.
179. Yun J, Rothrock RJ, Canoll P, Bruce JN. Convection-enhanced delivery for targeted delivery of antiglioma agents: the translational experience. J Drug Deliv (2013) 2013:107573. doi:10.1155/2013/107573.
180. Kong G, Braun RD, Dewhirst MW. Hyperthermia enables tumor-specific nanoparticle delivery: effect of particle size. Cancer Res (2000) 60(16):4440-5.
181. Frenkel V. Ultrasound mediated delivery of drugs and genes to solid tumors. Adv Drug Deliv Rev (2008) 60(10):1193-208. doi:10.1016/j.addr.2008.03.007.
182. Alitalo A, Detmar M. Interaction of tumor cells and lymphatic vessels in cancer progression. Oncogene (2012) 31(42):4499-508. doi:10.1038/onc.2011.602.
183. Tammela T, Zarkada G, Wallgard E, Murtomäki A, Suchting S, Wirzenius M, et al. Blocking VEGFR-3 suppresses angiogenic sprouting and vascular network formation. Nature (2008) 454(7204):656-60. doi:10.1038/nature07083.
184. Azzi S, Hebda JK, Gavard J. Vascular permeability and drug delivery in cancers. Front Oncol (2013) 3:211. doi:10.3389/fonc.2013.00211.
185. García-Román J, Zentella-Dehesa A. Vascular permeability changes involved in tumor metastasis. Cancer Lett (2013) 335(2):259-69. doi:10.1016/j.canlet.2013.03.005.
186. Gavard J, Patel V, Gutkind JS. Angiopoietin-1 prevents VEGF-induced endothelial permeability by sequestering Src through mDia. Dev Cell (2008) 14(1):25-36. doi:10.1016/j.devcel.2007.10.019.
187. Jain RK. Normalizing tumor microenvironment to treat cancer: bench to bedside to biomarkers. J Clin Oncol (2013) 31(17):2205-18. doi:10.1200/JCO.2012.46.3653.
188. Sorensen AG, Emblem KE, Polaskova P, Jennings D, Kim H, Ancukiewicz M, et al. Increased survival of glioblastoma patients who respond to antiangiogenic therapy with elevated blood perfusion. Cancer Res (2012) 72(2):402-7; Erratum in: Cancer Res (2012) 72(5):1316. Cancer Res (2012) 72(2). doi:10.1158/0008-5472.CAN-11-2464.
189. Gerstner ER, Batchelor TT. Antiangiogenic therapy for glioblastoma. Cancer J (2012) 18(1):45-50. doi:10.1097/PPO.0b013e3182431c6f.
190. Pishko GL, Muldoon LL, Pagel MA, Schwartz DL, Neuwelt EA. Vascular endothelial growth factor blockade alters magnetic resonance imaging biomarkers of vascular function and decreases barrier permeability in a rat model of lung cancer brain metastasis. Fluids Barriers CNS (2015) 12:5. doi:10.1186/2045-8118-12-5.
191. Li JL, Sainson RC, Shi W, Leek R, Harrington LS, Preusser M, et al. Delta-like 4 Notch ligand regulates tumor angiogenesis, improves tumor vascular function, and promotes tumor growth in vivo. Cancer Res (2007) 67(23):11244-53. doi:10.1158/0008-5472.CAN-07-0969.
192. Casey SC, Amedei A, Aquilano K, Azmi AS, Benencia F, Bhakta D, et al. Cancer prevention and therapy through the modulation of the tumor microenvironment. Semin Cancer Biol (2015). doi:10.1016/j.semcancer.2015.02.007.
193. Abès R, Teillaud JL. Modulation of tumor immunity by therapeutic monoclonal antibodies. Cancer Metastasis Rev (2011) 30(1):111-24. doi:10.1007/s10555-011-9282-3.
194. Leibovici J, Itzhaki O, Huszar M, Sinai J. The tumor microenvironment: part 1. Immunotherapy (2011) 3(11):1367-84. doi:10.2217/imt.11.111.
195. Gillies RJ, Raghunand N, Karczmar GS, Bhujwalla ZM. MRI of the tumor microenvironment. J Magn Reson Imaging (2002) 16(4):430-50; Erratum in: J Magn Reson Imaging (2002) 16(6):751. doi:10.1002/jmri.10181.
196. Penet MF, Krishnamachary B, Chen Z, Jin J, Bhujwalla ZM. Molecular imaging of the tumor microenvironment for precision medicine and theranostics. Adv Cancer Res (2014) 124:235-56. doi:10.1016/B978-0-12-411638-2.00007-0.
197. Khawar IA, Kim JH, Kuh HJ. Improving drug delivery to solid tumors: priming the tumor microenvironment. J Control Release (2015) 201:78-89. doi:10.1016/j.jconrel.2014.12.018.
198. Narunsky L, Oren R, Bochner F, Neeman M. Imaging aspects of the tumor stroma with therapeutic implications. Pharmacol Ther (2014) 141(2):192-208. doi:10.1016/j.pharmthera.2013.10.003.
199. Kuszyk BS, Corl FM, Franano FN, Bluemke DA, Hofmann LV, Fortman BJ, et al. Tumor transport physiology: implications for imaging and imaging-guided therapy. AJR Am J Roentgenol (2001) 177(4):747-53. doi:10.2214/ajr.177.4.1770747.
200. Kim M, Gillies RJ, Rejniak KA. Current advances in mathematical modeling of anti-cancer drug penetration into tumor tissues. Front Oncol (2013) 3:278. doi:10.3389/fonc.2013.00278.
201. Albini A, Pennesi G, Donatelli F, Cammarota R, De Flora S, Noonan DM. Cardiotoxicity of anticancer drugs: the need for cardio-oncology and cardio-oncological prevention. J Natl Cancer Inst (2010) 102(1):14-25. doi:10.1093/jnci/djp440.
202. Burlá AK, Lobato NS, Fortes ZB, Oigman W, Neves MF. Cardiac fibrosis and vascular remodeling are attenuated by metformin in obese rats. Int J Cardiol (2013) 165(3):483-7. doi:10.1016/j.ijcard.2011.09.012.
203. Orecchioni S, Reggiani F, Talarico G, Mancuso P, Calleri A, Gregato G, et al. The biguanides metformin and phenformin inhibit angiogenesis, local and metastatic growth of breast cancer by targeting both neoplastic and microenvironment cells. Int J Cancer (2015) 136(6):E534-44. doi:10.1002/ijc.29193.
204. Baronzio G, Freitas I, Kwaan HC. Tumor microenvironment and hemorheological abnormalities. Semin Thromb Hemost (2003) 29(5):489-97. doi:10.1055/s-2003-44557.
205. Leguerney I, Lassau N, Koscielny S, Rodrigues M, Massard C, Rouffiac V, et al. Combining functional imaging and interstitial pressure measurements to evaluate two anti-angiogenic treatments. Invest New Drugs (2012) 30(1):144-56. doi:10.1007/s10637-010-9543-y.
206. Maeda H. Toward a full understanding of the EPR effect in primary and metastatic tumors as well as issues related to its heterogeneity. Adv Drug Deliv Rev (2015). doi:10.1016/j.addr.2015.01.002.
207. Jang SH, Wientjes MG, Lu D, Au JL. Drug delivery and transport to solid tumors. Pharm Res (2003) 20(9):1337-50. doi:10.1023/A:1025785505977.
208. Ribatti D. Vascular normalization: a real benefit? Cancer Chemother Pharmacol (2011) 68(2):275-8. doi:10.1007/s00280-011-1683-z.
209. Datta NR, Ordóñez SG, Gaipl US, Paulides MM, Crezee H, Gellermann J, et al. Local hyperthermia combined with radiotherapy and-/or chemotherapy: Recent advances and promises for the future. Cancer Treat Rev (2015). doi:10.1016/j.ctrv.2015.05.009.
210. Hurwitz M, Stauffer P. Hyperthermia, radiation and chemotherapy: the role of heat in multidisciplinary cancer care. Semin Oncol (2014) 41(6):714-29. doi:10.1053/j.seminoncol.2014.09.014.
211. Wiig H, Keskin D, Kalluri R. Interaction between the extracellular matrix and lymphatics: consequences for lymphangiogenesis and lymphatic function. Matrix Biol (2010) 29(8):645-56. doi:10.1016/j.matbio.2010.08.001.
212. Rejniak KA, Estrella V, Chen T, Cohen AS, Lloyd MC, Morse DL. The role of tumor tissue architecture in treatment penetration and efficacy: an integrative study. Front Oncol (2013) 3:111. doi:10.3389/fonc.2013.00111.